Nature

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Figure 1: PD-L1 prevalence and response rates in patients with UBC. Table 2 Treatment-related adverse events occurring in two or more patients (grade 1–2) or in one patient (grade 3–4) Full size table ...
Business Wire

FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) in Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it has received a second Breakthrough Therapy Designation from ...
Nature

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Pre-clinical studies demonstrated that anti-PD-L1 treatment of mice bearing implanted syngeneic tumours could lead to tumour regression and the induction of protective immune memory in the setting of ...
Healio

FDA grants breakthrough therapy designation to MPDL3280A for PDL1–positive NSCLC

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA granted breakthrough therapy ...
Business Wire

Genentech’s Investigational Immunotherapy MPDL3280A Doubled the Likelihood of Survival Compared with Chemotherapy in People with a Specific Type of Lung Cancer

“In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical ...
Cure Today

FDA Grants Breakthrough Status to PD-L1 Inhibitor MPDL3280A in Lung Cancer

The PD-L1 inhibitor MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed on prior therapy. The PD-L1 ...